KalVista Pharmaceuticals Business Summary

KalVista Pharmaceuticals, Inc. (KALV) is a commercial-stage biopharmaceutical company that generates revenue primarily through the global sale of EKTERLY (sebetralstat), the first FDA-approved oral on-demand treatment for hereditary angioedema (HAE). Following its July 2025 U.S. launch and subsequent European approvals, the company reported unaudited 2025 revenues of $49 million, with $35 million generated in the fourth quarter alone. Its business model focuses on the discovery and commercialization of small-molecule protease inhibitors, specifically targeting the kallikrein-kinin system to address unmet needs in rare diseases. KalVista operates within a highly competitive HAE landscape, contending with BioCryst Pharmaceuticals (Orladeyo), Takeda (Takhzyro), and CSL Behring (Haegarda). While these competitors dominate the prophylactic and injectable on-demand segments, KalVista occupies a unique market niche as the sole provider of a rapid-acting oral therapeutic for acute attacks, significantly reducing the treatment burden compared to traditional subcutaneous or intravenous options. Leadership is spearheaded by CEO Benjamin L. Palleiko, who previously served as the company’s President and CFO; Palleiko is a former U.S. Naval Aviator with an MBA from the University of Chicago and extensive experience in life sciences investment banking. The executive team includes Chief Operating Officer Bilal Arif and Chief Financial Officer Brian Piekos, both appointed in late 2025 to scale global commercial operations. The clinical strategy is directed by Chief Medical Officer Dr. Paul K. Audhya and Chief Development Officer Dr. Christopher M. Yea, a co-inventor of the company’s core technology. Founded in 2011 by Robert Haigh and former CEO Andrew Crockett, KalVista is backed by a sophisticated investor base including Venrock, Novo Holdings, and Vivo Capital. The Board of Directors, chaired by Dr. Martin Edwards, features industry veterans such as Dr. Brian J. G. Pereira and Laurence Reid, providing deep expertise in orphan drug development and strategic exits.